ArticleJournal of the National Cancer Institute2026
FDA approvals for pediatric cancer indications using children's oncology group associated trials data.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe Children's Oncology Group (COG), formed in 2000, is a large international trial network that has conducted over 330 clinical trials for pediatric, adolescent, and young adult cancers. The role of COG trial data for Food and Drug Administration (FDA) approval of pediatric oncology indications was assessed since 2000.
methodsAll FDA approvals for pediatric oncology indications between January 1, 2000, and December 31, 2024, were reviewed. Data were collected from the FDA website, clinicaltrials.gov and COG database.
resultsTwenty-five (47%) of the 53 FDA pediatric indication approvals for 37 different drugs or biologics utilized COG clinical trial data for the approval of the pediatric indication. The 21 COG studies used for approvals were supported by three different partnership models, with 14 indications (26% of all pediatric approvals) supported by data from 15 trials utilizing the COG cooperative agreement award from the National Cancer Institute (NCI).
conclusionAlmost half of FDA approved pediatric indications for oncology therapeutics were supported by data from COG trials, highlighting the effectiveness of this public-private partnership model in producing the level of clinical evidence required for regulatory success.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.